Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07791758
PHASE1/PHASE2

A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

Sponsor: Nanjing Leads Biolabs Co.,Ltd

View on ClinicalTrials.gov

Summary

This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.

Official title: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

369

Start Date

2026-09-04

Completion Date

2030-09-04

Last Updated

2026-09-02

Healthy Volunteers

No

Interventions

DRUG

LBL-024 for Injection

intravenous infusion.

DRUG

Bevacizumab injection

intravenous infusion.

DRUG

Oxaliplatin injection

intravenous infusion.

DRUG

Capecitabine tablets

Oral.

DRUG

Fruquintinib Capsules

Oral.

Locations (10)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

The Sixth Affiliated Hospital Sun Yat-sen University

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Henan, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Shandong Cancer Hospital

Jinan, Shandong, China

Shanghai GoBroad Cancer Hospital

Shanghai, Shanghai Municipality, China

Sichuan Cancer Hospital

Chengdu, Sichuan, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China